176 related articles for article (PubMed ID: 32536999)
1. Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Li H; Li H; Waresijiang Y; Chen Y; Li Y; Yu L; Li Y; Liu L
Exp Ther Med; 2020 Jul; 20(1):315-324. PubMed ID: 32536999
[TBL] [Abstract][Full Text] [Related]
2. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma.
Huang R; Zhang X; Sophia S; Min Z; Liu X
Anticancer Drugs; 2018 Apr; 29(4):364-370. PubMed ID: 29481474
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.
Müller BM; Jana L; Kasajima A; Lehmann A; Prinzler J; Budczies J; Winzer KJ; Dietel M; Weichert W; Denkert C
BMC Cancer; 2013 Apr; 13():215. PubMed ID: 23627572
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway.
Ma S; Liu T; Xu L; Wang Y; Zhou J; Huang T; Li P; Liu H; Zhang Y; Zhou X; Cui Y; Zang X; Wang Y; Guan F
J Cell Physiol; 2019 Dec; 234(12):22400-22410. PubMed ID: 31120582
[TBL] [Abstract][Full Text] [Related]
6. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
[TBL] [Abstract][Full Text] [Related]
7. HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9.
Wang F; Qi Y; Li X; He W; Fan QX; Zong H
Clin Invest Med; 2013 Apr; 36(2):E87-94. PubMed ID: 23544610
[TBL] [Abstract][Full Text] [Related]
8. RANK overexpression as a novel esophageal cancer marker: validated immunohistochemical analysis of two different ethnicities.
Cui X; Peng H; Jin J; Li T; Zhang S; Jin T; Li S; Liu C; Liang W; Li F; Chen Y
Int J Clin Exp Pathol; 2015; 8(2):2249-58. PubMed ID: 25973136
[TBL] [Abstract][Full Text] [Related]
9. Expression of Twist, Slug and Snail in esophageal squamous cell carcinoma and their prognostic significance.
Xu S; Zhou Y; Biekemitoufu H; Wang H; Li C; Zhang W; Ma Y
Oncol Lett; 2021 Mar; 21(3):184. PubMed ID: 33574923
[TBL] [Abstract][Full Text] [Related]
10. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma.
Zhong L; Zhou S; Tong R; Shi J; Bai L; Zhu Y; Duan X; Liu W; Bao J; Su L; Peng Q
Invest New Drugs; 2019 Aug; 37(4):616-624. PubMed ID: 30168013
[TBL] [Abstract][Full Text] [Related]
11. HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.
Li J; Jin C; Sun L; Wang B; Hua P; Zhang Y
Clin Epigenetics; 2021 Apr; 13(1):96. PubMed ID: 33926524
[TBL] [Abstract][Full Text] [Related]
12. Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
Seo J; Min SK; Park HR; Kim DH; Kwon MJ; Kim LS; Ju YS
J Breast Cancer; 2014 Dec; 17(4):323-31. PubMed ID: 25548579
[TBL] [Abstract][Full Text] [Related]
13. HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
Li S; Wang F; Qu Y; Chen X; Gao M; Yang J; Zhang D; Zhang N; Li W; Liu H
Oncol Lett; 2017 Jan; 13(1):403-409. PubMed ID: 28123574
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma.
Deng F; Zhou K; Cui W; Liu D; Ma Y
Int J Clin Exp Pathol; 2015; 8(3):3045-53. PubMed ID: 26045816
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
[TBL] [Abstract][Full Text] [Related]
16. Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.
Wang H; Kohashi K; Yoshizumi T; Okumura Y; Tanaka Y; Shimokawa M; Iwasaki T; Aishima S; Maehara Y; Oda Y
Hum Pathol; 2017 Jun; 64():69-75. PubMed ID: 28411180
[TBL] [Abstract][Full Text] [Related]
17. HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
Ler SY; Leung CH; Khin LW; Lu GD; Salto-Tellez M; Hartman M; Iau PT; Yap CT; Hooi SC
Oncol Rep; 2015 Nov; 34(5):2238-50. PubMed ID: 26352599
[TBL] [Abstract][Full Text] [Related]
18. Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro.
Lutz L; Fitzner IC; Ahrens T; Geißler AL; Makowiec F; Hopt UT; Bogatyreva L; Hauschke D; Werner M; Lassmann S
Am J Cancer Res; 2016; 6(3):664-76. PubMed ID: 27152243
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of PI3K in esophageal squamous cell carcinoma].
Zhang Y; Liu YP; Du K; Wang H; Wang XL
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):594-8. PubMed ID: 22325219
[TBL] [Abstract][Full Text] [Related]
20. X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer.
Han Y; Zhang Y; Yang LH; Mi XY; Dai SD; Li QC; Xu HT; Yu JH; Li G; Zhao J; Han C; Yuan XM; Wang EH
Radiat Oncol; 2012 Oct; 7():183. PubMed ID: 23110995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
